Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
BOTHELL, Wash., and TOKYO, July 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...
TOKYO, July 2, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has received an approval for the marketing application of...
TOKYO, June 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that results from the pivotal Phase 3 PROSPER trial, which...
Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in...
Read more about Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year
Follow us
